

| Name of the issuer: | Krsnaa Diagnostics Limited | Last updated on | 21-Nov-22 | |
|--|--|--|---|---|
| 1 Type of Issue (PO / FPO) | IPO | | | |
| 2 Issue Size (Rs. Cr) | 1213.3 | | | |
| - Fresh Issue Size (Rs. Cr) | 400.0 | | | |
| - Offer for Sale Component (Rs. Cr) | 813.3 | | | |
| Source: Post Issue Monitoring Report | | | | |
| 3 Grade of issue along with name of the rating agency | | | | |
| Name | Not Applicable | | | |
| Grade | Not Applicable | | | |
| 4 Subscription Level (Number of times) | 36.05* | | | |
| Source: Post Issue Monitoring Report *The above figure is after technical rejections and includes anchor | | | | |
| 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges | | | | |
| Particulars | % | | | |
| (i) allotment in the issue ⁽¹⁾ | 30.08% | | | |
| (ii) at the end of the 1st Quarter immediately after the listing of the issue | 36.16% | | | |
| (iii) at the end of 1st FY (March 31, 2022) | 33.13% | | | |
| (iv) at the end of 2nd FY (March 31, 2023)* | Not Available | | | |
| (v) at the end of 3rd FY (March 31, 2024)* | Not Available | | | |
| * QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed. (1) Source: Minutes of Basis of Allotment. Includes allotment to Anchor Investors | | | | |
| 6 Financials of the issuer | | | | |
| | | | (In Rs. Crore) | |
| Parameters (consolidated) | 1st FY (March 31, 2022) | 2nd FY (March 31, 2023)* | 3rd FY (March 31, 2024)* | |
| Income from operations | 470.36 | Not Available | Not Available | |
| Net Profit for the period | 68.39 | Not Available | Not Available | |
| Paid-up equity share capital | 15.70 | Not Available | Not Available | |
| Reserves excluding revaluation reserves | 668.71 | Not Available | Not Available | |
| * Financials not disclosed as reporting for the relevant fiscal year has not been completed. | | | | |
| 7 Trading Status in the scrip of the issuer | | | | |
| Company's Equity Shares are listed on both the BSE Limited and the NSE. The Shares have not been suspended or delisted. | | | | |
| Particulars | Status | | | |
| (i) at the end of 1st FY (March 31, 2022) | Frequently traded | | | |
| (ii) at the end of 2nd FY (March 31, 2023)* | Not Available | | | |
| (iii) at the end of 3rd FY (March 31, 2024)* | Not Available | | | |
| * Trading status not disclosed as the relevant fiscal year has not been completed. | | | | |
| 8 Change in Directors of issuer from the disclosures in the offer document | | | | |
| Particulars | Name of the Director | Appointed / Resigned | | |
| (i) at the end of 1st FY (March 31, 2022) | - | - | | |
| (ii) at the end of 2nd FY (March 31, 2023)# | Adesh Kumar Gupta | Appointed | | |
| | Prakash Iyer | Resigned | | |
| (iii) at the end of 3rd FY (March 31, 2024)* | Not Available | Not Available | | |
| # Updated till Nov 21, 2022 * Changes in Directors not disclosed as the relevant fiscal year has not been completed. | | | | |
| 9 Status of implementation of project/ commencement of commercial production | | | | |
| (i) as disclosed in the offer document | Not applicable | | | |
| (ii) Actual implementation | Not applicable | | | |
| (iii) Reasons for delay in implementation, if any | Not applicable | | | |
| 10 Status of utilization of issue proceeds | | | | |
| (i) as disclosed in the offer document | | | (In Rs. Crore) | |
| Particulars | Total estimated amount/ expenditure | Estimated utilisation from Net Proceeds | Estimated Deployment (Financial Year 2022) | Estimated Deployment (Financial Year 2023) |
| Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra | 150.81 | 150.81 | 125.00 | 25.81 |
| Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company | 146.08 | 146.08 | 146.08 | 0.00 |
| General corporate purposes | 81.74 | 81.74 | 81.74 | 0.00 |
| Total | 378.63 | 378.63 | 352.82 | 25.81 |
| (ii) Actual utilization | | | (In Rs. Crore) | |
| Particulars | As of June 30, 2022 | | | |
| Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra | 77.82 | | | |
| Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company | 142.90 | | | |
| General corporate purposes | 0.50 | | | |
| Total | 221.22 | | | |
| (iii) Reasons for deviation, if any | None | | | |
| 11 Comments of monitoring agency, if applicable | | | | |
| (a) Comments on use of funds | | | | |
| (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document | No comments | | | |
| (c) Any other reservations expressed by the monitoring agency about the end use of funds | | | | |

12 Pricing Data

| | |
|----------------------------|-----------|
| Issue Price (Rs.): | 954 |
| Designated Stock Exchange: | NSE |
| Listing Date: | 16-Aug-21 |

| Price parameters | At close of listing day (Aug 16, 2021) | At close of 30th calendar day from listing day (Sep 14, 2021) ⁽¹⁾ | At close of 90th calendar day from listing day (Nov 13, 2021) ⁽²⁾ | As at the end of 1st FY after the listing of the issue (March 31, 2022) | | | As at the end of 2nd FY after the listing of the issue (March 31, 2023) ⁽³⁾ | | | As at the end of 3rd FY after the listing of the issue (March 31, 2024) ⁽⁴⁾ | | |
|---|--|--|--|---|----------------------|---------------------|--|----------------------|---------------------|--|----------------------|---------------------|
| | | | | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on Designated Stock Exchange | 987.00 | 864.15 | 689.45 | 488.70 | 1,099.70 | 480.00 | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| NIFTY 50 | 16,563.05 | 17,380.00 | 18,102.75 | 17,464.75 | 18,604.45 | 15,671.45 | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| Sectoral Index ⁽⁵⁾ | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |

- Note:
- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 - (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 - (3) High and Low based on intra day prices.
 - (4) Pricing data not disclosed as the relevant fiscal year has not completed.
 - (5) There is no sectoral index

13 Basis for Issue Price

| Accounting ratio | As disclosed in the offer document ⁽¹⁾ | At the end of 1st FY (March 31, 2022) | At the end of 2nd FY (March 31, 2023) ⁽²⁾ | At the end of 3rd FY (March 31, 2024) ⁽²⁾ |
|---------------------------------------|---|---------------------------------------|--|--|
| Issuer: | | | | |
| Basic | 71.86 | 22.89 | Not Available | Not Available |
| Peer Group: | | | | |
| Metropolis Healthcare Limited (Basic) | 35.97 | 41.87 | Not Available | Not Available |
| Dr. Lal Pathlabs Limited (Basic) | 35.33 | 41.70 | Not Available | Not Available |
| Industry Avg: | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Issuer: | | | | |
| Basic | 77.88 | 21.35 | Not Available | Not Available |
| Peer Group: | | | | |
| Metropolis Healthcare Limited (Basic) | 77.65 | 48.64 | Not Available | Not Available |
| Dr. Lal Pathlabs Limited (Basic) | 94.32 | 62.52 | Not Available | Not Available |
| Industry Avg: | 85.99 | 55.58 | Not Available | Not Available |
| Issuer: | | | | |
| RoNW (%) | 79.76% | 9.99 | Not Available | Not Available |
| Peer Group: | | | | |
| Metropolis Healthcare Limited | 25.91 | 24.17 | Not Available | Not Available |
| Dr. Lal Pathlabs Limited | 23.42 | 22.78 | Not Available | Not Available |
| Industry Avg: | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Issuer: | | | | |
| NAV per share | 85.27 | 217.98 | Not Available | Not Available |
| Peer Group: | | | | |
| Metropolis Healthcare Limited | 138.23 | 173.18 | Not Available | Not Available |
| Dr. Lal Pathlabs Limited | 149.39 | 180.93 | Not Available | Not Available |
| Industry Avg: | Not Applicable | Not Applicable | Not Applicable | Not Applicable |

- Notes:**
- (1) Sourced from Prospectus.
 - (2) Information not provided as the relevant fiscal year has not completed.
- Key ratios for the Company for 1st FY and 2nd FY stated above are calculated as follows:
- (i) Basic and diluted earnings per Equity Share are based on the Annual Reports for the relevant years
 - (ii) P/E - Closing Market Price on BSE as of relevant fiscal year / EPS (diluted); Also disclosed EPS (basic) for the Issuer
 - (iii) RoNW - Net profit after tax attributable to the owners divided by net worth at the end of the relevant period
 - (iv) NAV per share - Net worth at the end of the relevant period divided by Total Equity Shares Outstanding as of fiscal year end

14 Any other material information

| Date of disclosure to Designated Stock Exchange | Announcement |
|---|--|
| 26-Aug-21 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), this is to inform you that as a part of the Agreement with Government of Punjab (Agreement) for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company will be inaugurating its first Diagnostics Center of the above mentioned Agreement at Mohali, Punjab on August 31, 2021 which will provide CT Scan, MRI & Pathology Laboratory facilities. |
| 30-Sep-21 | Krсна Diagnostcs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2021, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krсна Diagnostcs Limited (the Company) is scheduled to be held on Monday, 11th October, 2021, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter and six months ending on 30th September, 2021 and to take on record, the Limited Review Report thereon |
| 6-Oct-21 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 submitted |
| 7-Oct-21 | Statement Of Investor Complaints For The Quarter Ended September 2021 submitted |
| 11-Oct-21 | Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended on 30th September, 2021 |
| 11-Oct-21 | Change in the Key Managerial Personnel: The resignation of CS Manisha Chitopekar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 and appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 11-Oct-21 | Pursuant to the provisions of Regulation 32 (1) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th September, 2021. |
| 11-Oct-21 | Press Release - Unaudited Financial Results for the quarter and six months ended on 30th September, 2021. |
| 11-Oct-21 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Earnings Presentation for on Unaudited Financial Results of the Company for the period ended on 30th September, 2021. |
| 11-Oct-21 | The resignation of CS Manisha Chitopekar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 |
| 11-Oct-21 | Appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015. |
| 13-Oct-21 | Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and six months ended on 30th September, 2021, published in Financial Express (All Editions) and Loksaatta (Pune Edition), both dated on 13th October, 2021. |
| 19-Oct-21 | Please find enclosed the transcript of the Q2 and H1 FY22 Earnings Conference Call conducted on 12th October, 2021, for your information and records. |
| 9-Nov-21 | Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions for the half year ended 30th September, 2021. |
| 12-Nov-21 | Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 30th September, 2021. |
| 4-Dec-21 | Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that based on CRISIL Rating letter dated 03rd December, 2021, the credit rating of the Company, has been upgraded as per the attached letter. The detailed report on Credit Rating issued by CRISIL is accessible on the following link: https://www.crisil.com/mnt/wshare/Ratings/RatingList/RatingDocs/KrsnaaDiagnostcsLimited_December%202021_RR_282773.html |
| 24-Dec-21 | Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project. |
| 3-Jan-22 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Inauguration Of Diagnostics Centers Under Punjab Radiology and Pathology Project. |
| 5-Jan-22 | Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended December 31, 2021, received from KFin Technologies Private Limited (SEBI Registration Number INR00000221), Registrar and Share Transfer Agent of the Company. It is requested to take this intimation on record and acknowledge receipt of the same. |
| 7-Jan-22 | Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project. |
| 11-Jan-22 | Statement Of Investor Complaints For The Quarter Ended December 2021 |
| 17-Jan-22 | Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that ICRA, has assigned a long-term rating of [CRA]A (pronounced ICRA A) and a short-term rating of [CRA]A1 (pronounced ICRA A one) for INR 85.00 Crore Line of Credit (LOC) of the Company. The Outlook on the long-term rating is Stable. |
| 22-Jan-22 | Inauguration of Diagnostics Center at K. B. Bhabha Hospital, Kurla, Mumbai. |
| 24-Jan-22 | Krсна Diagnostcs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krсна Diagnostcs Limited (the Company) is scheduled to be held on Monday, 31st January, 2022, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter ended on 31st December, 2021 and to take on record, the Limited Review Report thereon. The Company will hold investor / analyst call post Board Meeting. The details of the said call will be intimated to the stock exchanges separately in due course. It is requested to take the same on your records. |
| 31-Jan-22 | Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended 31st December, 2021 along with Limited Review report thereon |

| | |
|-----------|---|
| 31-Jan-22 | Outcome of Board Meeting |
| 31-Jan-22 | Pursuant to the provisions of Regulation 32 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Request you to take the same on your records. |
| 31-Jan-22 | This has reference to the captioned subject and our earlier communication w.r.t. a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Kindly find attached herewith, a revised / corrected Statement of deviation(s) or variation(s). In the earlier statement of deviation(s) or variation(s) the amount raised was wrongly mentioned as INR 400 Million instead of INR 400 Crores. Kindly take the revised disclosure on your records. |
| 31-Jan-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Unaudited Financial Results of the Company for the quarter and nine months ended on 31 st December, 2021. Request you to take the same on your records. |
| 2-Feb-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2021, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 02nd February, 2022. Financial Statement for the quarter and nine months ended as mentioned above has also been published on website (www.krsnaadiagnostics.com) of the Company. Request you to take the same on your records. |
| 2-Feb-22 | Q3FY2022 Earnings Presentation |
| 8-Feb-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Department of Medical Health & Family Welfare Government of Uttar Pradesh has awarded a Tender for providing CT Scan Services in the 8 District Hospitals in the State of Uttar Pradesh to the Company. |
| 8-Feb-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Health Department, U.T., Chandigarh has awarded a Tender for Development, Operation and Maintenance of Radiology Imaging Diagnostic Centre in The Government Multi Speciality Hospital, Sector - 16, Chandigarh (GMSH-16) on Public Private Partnership (PPP) basis. |
| 9-Feb-22 | The transcript of the Q3FY22 Earnings Conference Call conducted on 03rd February, 2022. |
| 11-Jan-22 | Inauguration of Diagnostics Center at Bilaspur, Himachal Pradesh. |
| 12-Feb-22 | Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2015 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith, a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 31st December, 2021. You are requested to take the same on your record |
| 21-Feb-22 | Winning of Tender for providing Diagnostic / Laboratory Services in H.P. Govt. Health Institutions in entire State of Himachal Pradesh to the Company. |
| 14-Mar-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Mr. Shivarama Rao has tendered his resignation from the post of Chief Operating Officer of the Company effective from closing of business hours on Monday, 14th March, 2022. |
| 14-Mar-22 | Please find enclosed herewith a press release titled "Krsnaa Diagnostics strengthens its leadership with the appointment of a new Chief Operating Officer", which is being released to Press. |
| 21-Mar-22 | Change of Name of Registrar and Share Transfer Agent of the Company from "KFin Technologies Private Limited" to "KFin Technologies Limited". |
| 28-Mar-22 | Inauguration of Diagnostics Center at Solan, Himachal Pradesh. |
| 31-Mar-22 | Pursuant to the relevant circulars issued by BSE Limited and National Stock Exchange of India Limited, read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, this is to intimate that the trading window for dealing in shares of the Company for all Directors, Key Managerial Personnel, Designated Employees, and other connected persons, will remain closed from 1st April, 2022 till end of two calendar days from the date of submission of financial results of the Company for the quarter and year ending on 31st March, 2022, to the Stock Exchanges, unless decided otherwise. The date of the Board Meeting to consider and approve financial results for the quarter and year ending on 31st March, 2022, will be informed in due course. |
| 5-Apr-22 | Statement Of Investor Complaints For The Quarter Ended March 2022 |
| 5-Apr-22 | Compliance Certificate As Per Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31st March, 2022 |
| 5-Apr-22 | Certificates as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2022. |
| 8-Apr-22 | As per Regulation 40(10) of SEBI LODR, we are submitting herewith a Certificate dated 07th April, 2022 issued by M/S Dinesh Birla & Associates, Company Secretaries, pertaining to yearly audit conducted by them pursuant to Regulation 40(9) SEBI LODR for the year ended on 31st March, 2022. |
| 27-Apr-22 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate - Annexure A |
| 13-May-22 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 |
| 14-May-22 | Monitoring Agency Report for the quarter ended 31st March, 2022 submitted |
| 14-May-22 | Statement Of Deviation(S) Or Variation(S) for the quarter ended on 31st March, 2022 submitted |
| 21-May-22 | Krsnaa Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and other applicable provisions, rules, and regulations, if any, this is to inform you that a meeting of Board of Directors (Board) of the Company, is scheduled to be held on Saturday, 28th May, 2022, inter-alia, to consider and approve: 1. Financial Results: a. Audited (Standalone and Consolidated) Financial Results, for the quarter ended on 31st March, 2022, and to take on record, the Auditor's Report thereon; and b. Audited (Standalone and Consolidated) Financial Statements of the Company, for the financial year ended on 31st March, 2022, and to take on record, the Auditor's Report thereon. 2. Proposal for recommendation of Final Dividend, for the financial year 2021-22. It is requested to take the same on your records. |
| 24-May-22 | Report of Monitoring Agency for the Initial Public Offer- Revised submitted |
| 27-May-22 | In compliance with the SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed the Annual Secretarial Compliance report for the year ended 31st March, 2022, issued by Dinesh Birla & Associates, Practicing Company Secretary, Secretarial Auditor of the Company. It is requested to take the same on your records. |
| 28-May-22 | Outcome of Board Meeting held on 28-May-2022 to consider financial statements for the period ended March 2022, Dividend and change in Board of Directors. |
| 28-May-22 | Board of Directors at its meeting held on 28-May-2022, Declared Dividend of Rs. 2.50 per equity share |
| 28-May-22 | Change in Board of Directors: 1. Appointment of Director Appointment of Mr. Adesh Kumar Gupta (DIN: 00020403) as Independent Director, on the Board of the Company, for a term of 5 years effective from 28th May, 2022, subject to Member's and other applicable approval(s). Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are enclosed as Annexure A. 2. Mr. Prakash Iyer (DIN: 00529591), has tendered his resignation from the post of Independent Director of the Company w.e.f. close of business hours on 28th May, 2022. The same has been taken on record by the Board of Directors in the Meeting held today. Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are enclosed as Annexure B. |
| 28-May-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022. Request you to take the same on your records. |
| 28-May-22 | With reference to captioned subject, please note that the Company had filed the Annual Secretarial Compliance report (the Report) for the year ended 31st March, 2022, issued by Dinesh Birla & Associates, Practicing Company Secretary, Secretarial Auditor of the Company on 27th May, 2022. However, there is a small correction in the Report w.r.t. change of date on for the heading on Page no. 2 wherein the date was inadvertently mentioned as 31st March, 2021 instead of 31st March, 2022. There is no other material change in the Report. It is requested to take the revised file of the Report on your records. |
| 30-May-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 30th May, 2022. |
| 31-May-22 | This has reference to the captioned subject and our earlier communication dated 28th May, 2022 regarding resignation of Mr. Prakash Iyer (DIN: 00529591) as an Independent Director of the Company effective from close of business hours on 28th May, 2022. We hereby submit additional information w.r.t. resignation of Mr. Iyer pursuant to the provisions of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure A to this Letter along with a copy of the Resignation Letter in this behalf. It is requested to take this intimation on your records. |
| 31-May-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Audited Financial Results of the Company for quarter and year ended on 31st March, 2022. Request you to take the same on your records. |
| 7-Jun-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Company has been awarded contract in the state of Tripura by the Mission Director, National Health Mission, State Health & Family Welfare Society, Tripura for Image Transmission & Reporting of Radiology Images and Selective Radiology Services ("X-ray Tele Radiology Services"). Krsnaa Diagnostics now has its footprint across 15 states with addition of State of Tripura where it will be having presence across all districts. We have enclosed, the disclosure in terms of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure I to this letter. Request you to take the same on your records. |
| 9-Jun-22 | Please find enclosed the transcript of the Q4 and FY22 Earnings Conference Call conducted on 02nd June, 2022. Request you to take the same on your records. |
| 11-Jun-22 | Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed by SEBI Circular No. SEBI/HO/CFD/CMD/IR/P/2021/662 dated 22nd November 2021, for the half year ended on 31st March 2022. |
| 16-Jun-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics centers at three more locations viz. Ludhiana, Jalandhar and Tarn Taran. |
| 24-Jun-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Krsnaa, city and Municipal Council in Ludhiana District. Request you to take the same on your records. |
| 5-Jul-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that "The Office of the Medical Director, Indira Gandhi Hospital, Government of NCT of Delhi has awarded a Tender for establishment, operation and management of Radiology Unit (for providing MRI and CT Scan services) in the Department of Radiology in the premises of Indira Gandhi Hospital, Dwarka, Sector - 9, New Delhi -110077 on Public Private Partnership (PPP) basis. Krsnaa Diagnostics now has its footprints in the Capital of India. |
| 5-Jul-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Moga, Punjab. |
| 6-Jul-22 | Statement Of Investor Complaints For The Quarter Ended June 2022 |
| 6-Jul-22 | Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended 30th June, 2022, received from KFin Technologies Limited (Formerly known as KFin Technologies Private Limited (SEBI Registration Number INR00000221), Registrar and Share Transfer Agent of the Company. |
| 19-Jul-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that "Rajasthan Medical Education Society (Directorate of Medical Education), Government of Rajasthan" has awarded a Tender for Supply, Installation, Operation and Maintenance of CT Scan Center at Raj - MES Medical College located at Churu, a City in Rajasthan on Public Private Partnership (PPP) basis. |
| 21-Jul-22 | Reconstitution of Committees of the Board. |
| 25-Jul-22 | Krsnaa Diagnostics to add 40 New CT Scan centers after winning Maharashtra and Churu tenders - 40%+ addition to existing CT Scan contracts. Krsnaa has been awarded one of the largest tenders in Public Private Partnerships for providing CT Scan Services by Commissionerate of Health Services, Maharashtra. The contract includes installation and / or operation of 39 CT Scanners across 39 District / Sub district Hospitals in Maharashtra with project value of approximately INR 75 Crore. This will allow Krsnaa Diagnostics to expand its footprint and strengthen its presence in major cities as well as Tier II & Tier III locations across the State of Maharashtra. |
| 26-Jul-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of Postal Ballot as issued to the Members of the Company for seeking their approval by means of Postal Ballot through remote e-voting for the following ordinary resolution: 1. Appointment of Mr. Adesh Kumar Gupta (DIN: 00020403) as an Independent Director The remote e-voting period shall commence from 9.00 am (IST) on Thursday, 28th July, 2022 and end at 5.00 pm (IST) on Friday, 28th August, 2022. The results of the Postal Ballot will be declared on or before Sunday, 28th August, 2022. The above referred notice is also available on the website of the Company viz. https://krsnaadiagnostics.com . It is requested to take this intimation on record and acknowledge receipt of the same. |
| 27-Jul-22 | Postal Ballot Notice and e-voting Information. |
| 27-Jul-22 | This has reference to the Postal Ballot Notice dated 21st July, 2022, which has already been emailed to the shareholders of the Company on 26th July, 2022. A Corrigendum is being issued to inform the shareholders of the Company regarding amendments in the Postal Ballot Notice and explanatory statement. A copy of detailed corrigendum is enclosed herewith. Except as detailed in the attached corrigendum, all other terms and contents of the Postal Ballot Notice along with Explanatory Statement dated 21st July, 2022, shall remain unchanged. This corrigendum will also be available on the website of the Company https://krsnaadiagnostics.com . Please note that on and from the date hereof, the Postal Ballot Notice shall always be read in conjunction with this Corrigendum. Note: The e-voting period shall commence from 9.00 a.m (IST) on Thursday, 28th July, 2022 and end at 5.00 p.m. (IST) on Friday, 28th August, 2022, both days inclusive. |

| | |
|-----------|---|
| 28-Jul-22 | Krсна Diagnostіcs Lthas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022. Inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krсна Diagnostіcs Limited ("the Company") is scheduled to be held on Thursday, 04th August, 2022, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter ended on 30th June, 2022 and to take on record, the Limited Review Report thereon. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, and the underlying Code of the Company, the Trading Window for dealing in securities of the Company, is already closed with effect from 01st July, 2022. The Company will hold investor / analyst call post Board Meeting. The details of the said call will be intimated to the stock exchanges separately in due course. It is requested to take the same on your records |
| 29-Jul-22 | Pursuant to the provisions of Regulation 30 and Schedule III, Part A Para B of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of the policy for determination and disclosure of Material Event / Information of the Company, we would like to inform that the Income Tax Department conducted a search under the powers conferred to them by the provisions of the Section 132 of the Income Tax Act, 1961 at the premises of the Company and at other locations. The Company has provided all possible assistance to the officials and furnished all explanations, information and clarifications as desired by them and continue to co-operate with them in this matter. We also wish to thank our employees for their continuous and unconditional support. We wish to inform that the proceedings have absolutely no impact on the operational performance of the Company. This is for your kind information and records please |
| 1-Aug-22 | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Three more locations viz. Faridkot, Hoshiarpur and Phagwara. |
| 2-Aug-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a Statement being issued by the Company. |
| 4-Aug-22 | Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended on 30th June, 2022 along with Limited Review report thereon |
| 4-Aug-22 | Outcome of Board Meeting |
| 4-Aug-22 | Record date Intimation for Payment of final dividend |
| 4-Aug-22 | Pursuant to the provisions of Regulation 32 (f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th June, 2022. |
| 4-Aug-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022. |
| 4-Aug-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Unaudited Financial Results of the Company for the period ended on 30th June, 2022. |
| 6-Aug-22 | Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022, published in Financial Express (All Editions) and Lokсatta (Pune Edition), both dated on 06th August, 2022. Financial Statement for the quarter ended as mentioned above has also been published on website (www.krснаdiagnostics.com) of the Company. Request you to take the same on your records. |
| 12-Aug-22 | Monitoring Agency Report for the quarter ended 30th June, 2022. |
| 12-Aug-22 | Transcript of the Q1FY23 Earnings Call conducted on 05th August, 2022. |
| 25-Aug-22 | Pursuant to the applicable provisions of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant circular(s) issued by the Ministry of Corporate Affairs (MCA) and SEBI in this regards, please find enclosed herewith copies of newspaper advertisement(s) published in Financial Express (All Editions) and Lokсatta (Pune Edition), both dated on 25th August, 2022. Request you to take the same on your records. |

Notes:

The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.

For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and/or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.